Logo Logo Logo
  • Home
  • About Us
    • Organization
    • Members
    • Contact Us
  • Research & Publications
    • Therapeutics Letter
    • Drug Assessments
    • PharmacoEpidemiology
    • Blog
  • Prescribing Portraits
    • Register
  • Continuing Education
    • Events & Webinars
    • Podcasts & Videos
  • Subscribe
  • Donate
Logo Logo Logo Logo Logo Logo
  • Home
  • About Us
    • Organization
    • Members
    • Contact Us
  • Research & Publications
    • Therapeutics Letter
    • Drug Assessments
    • PharmacoEpidemiology
    • Blog
  • Prescribing Portraits
    • Register
  • Continuing Education
    • Events & Webinars
    • Podcasts & Videos
  • Subscribe
  • Donate
 

October 2004

Rofecoxib (Vioxx®) withdrawal generates uncertainty about COX-2s – Do product monographs adequately inform?

31 Oct [53] Rofecoxib (Vioxx®) withdrawal generates uncertainty about COX-2s – Do product monographs adequately inform?

Posted at 00:00h in Therapeutics Letter 0 Comments
Share

Product Monographs are legal documents that in effect transfer responsibility to the prescribing physician. At issue in this letter is whether the Product Monographs for rofecoxib and the other non-steroidal anti-inflammatory drugs marketed as COX-2...

Read More
Link icon

26 Oct Effect of periodic letters on evidence-based drug therapy on prescribing behaviour: a randomized trial

Posted at 23:55h in PharmacoEpidemiology 0 Comments
Share

Dormuth CR, Maclure M, Bassett K, Jauca C, Whiteside C, Wright JM Link to publication...

Read More

adverse effects adverse events antibacterial agents antidepressive agents biosimilars blood pressure chronic pain COPD covid-19 deprescribing Deprescriptions Diabetes Diabetes Mellitus Drug-Related Side Effects and Adverse Reactions drug safety empagliflozin exercise gabapentin Glycemic Control guidelines hypertension inappropriate prescribing JAKi Janus kinase inhibitor Mass Screening methods opioid analgesics opioids overdiagnosis oxycodone pain pharmacoepidemiology portrait pregabalin prescribing proton pump inhibitors psoriatic arthritis rheumatoid arthritis safety SGLT2 smoking cessation Sodium-Glucose Transporter 2 Inhibitors substance withdrawal syndrome tofacitinib tramadol

Therapeutics Initiative logo

Our mission is to provide physicians, nurse practitioners, pharmacists, allied health professionals, and the public with up-to-date, independent, evidence-based, practical information on healthcare interventions. More about us

The Therapeutics Initiative is part of the Department of Anesthesiology, Pharmacology & Therapeutics at UBC's Faculty of Medicine.

Donate

 

Contact

Therapeutics Initiative
Dept of Anesthesiology, Pharmacology & Therapeutics
Faculty of Medicine
University of British Columbia

300 - 2176 Health Sciences Mall
Vancouver, BC, Canada V6T 1Z3

210 - 1110 Government Street
Victoria, BC, Canada V8W 1Y2

Office: +1 604-822-0700
Send us a message

 

Subscribe for Updates

Want to stay abreast of new therapeutics information? Then subscribe to receive email notices of upcoming Therapeutics Letters, educational events, and other announcements. We promise not to spam you and you won’t hear from us more than a few times a month.

Subscribe

Located on the traditional, ancestral and unceded territory of the hən̓q̓əmin̓əm̓ speaking peoples, including the xʷməθkwəy̓əm (Musqueam), the Səl̓ílwətaʔ/Selilwitulh (Tsleil-Waututh), and the Skwxwú7mesh (Squamish) Nations, and on the lək̓ʷəŋən (Lekwungen) territory of the Songhees, Esquimalt and W̱SÁNEĆ peoples.

 
© Copyright 1994 - 2022 Therapeutics Initiative | Terms & Policies